ArticleEuropean thyroid journal2022
External validation of AIBx, an artificial intelligence model for risk stratification, in thyroid nodules.
Article in European thyroid journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Beyond genomics: artificial intelligence-powered diagnostics for indeterminate thyroid nodules-a systematic review and meta-analysis.Frontiers in endocrinology · 2025Pooled it
- From Bench-to-Bedside: How Artificial Intelligence is Changing Thyroid Nodule Diagnostics, a Systematic Review.The Journal of clinical endocrinology and metabolism · 2024Pooled it
- Article
- Artificial intelligence in thyroid nodules and cancer: clinical validation and real-world performance.Endocrine connections · 2026Article
- Machine Learning for diagnosis of malignant thyroid nodules based on thyroid ultrasound: Systematic review and meta-analysis of studies with external datasets.European journal of radiology open · 2026Article
- Role of Artificial Intelligence in Thyroid Cancer Diagnosis.Journal of clinical medicine · 2025Review
- XGBoost-based machine learning model combining clinical and ultrasound data for personalized prediction of thyroid nodule malignancy.Frontiers in endocrinology · 2025Article
- Application progress of artificial intelligence in managing thyroid disease.Frontiers in endocrinology · 2025Review
- Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review.Endocrine · 2024Review
- Deep learning to assist composition classification and thyroid solid nodule diagnosis: a multicenter diagnostic study.European radiology · 2024Article
- Artificial Intelligence in Thyroidology: A Narrative Review of the Current Applications, Associated Challenges, and Future Directions.Thyroid : official journal of the American Thyroid Association · 2023Review
- The Use of Artificial Intelligence in the Diagnosis and Classification of Thyroid Nodules: An Update.Cancers · 2023Review
- Incorporation of a machine learning pathological diagnosis algorithm into the thyroid ultrasound imaging data improves the diagnosis risk of malignant thyroid nodules.Frontiers in oncology · 2022Article
- A Glimpse into the Realm that Combines Artificial Intelligence and Endocrinology.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Artificial intelligence algorithms could be used to risk-stratify thyroid nodules and may reduce the subjectivity of ultrasonography. One such algorithm is AIBx which has shown good performance. However, external validation is crucial prior to clinical implementation. Materials and methods: Patients harboring thyroid nodules 1-4 cm in size, undergoing thyroid surgery from 2014 to 2016 in a single institution, were included. A histological diagnosis was obtained in all cases. Medullary thyroid cancer, metastasis from other cancers, thyroid lymphomas, and purely cystic nodules were excluded. Retrospectively, transverse ultrasound images of the nodules were analyzed by AIBx, and the results were compared with histopathology and Thyroid Imaging Reporting and Data System (TIRADS), calculated by experienced physicians. Results: Out of 329 patients, 257 nodules from 209 individuals met the eligibility criteria. Fifty-one nodules (20%) were malignant. AIBx had a negative predictive value (NPV) of 89.2%. Sensitivity, specificity, and positive predictive values (PPV) were 78.4, 44.2, and 25.8%, respectively. Considering both TIRADS 4 and TIRADS 5 nodules as malignant lesions resulted in an NPV of 93.0%, while PPV and specificity were only 22.4 and 19.4%, respectively. By combining AIBx with TIRADS, no malignant nodules were overlooked. Conclusion: When applied to ultrasound images obtained in a different setting than used for training, AIBx had comparable NPVs to TIRADS. AIBx performed even better when combined with TIRADS, thus reducing false negative assessments. These data support the concept of AIBx for thyroid nodules, and this tool may help less experienced operators by reducing the subjectivity inherent to thyroid ultrasound interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.